MEI Pharma (Nasdaq:MEIP) - Hisse Senedi Fiyatı, Haberler ve Analizler

MEIP Stoklara Genel Bakış

Klinik aşamada bir ilaç şirketi olan MEI Pharma, Inc. kanser tedavisi için çeşitli tedavilerin geliştirilmesine odaklanmaktadır. Daha fazla detay

MEIP temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

1 yıldan az nakit akışı var

Geliri 1 milyon ABD dolarından az ( $0 )

Anlamlı bir piyasa değeri yok ( $18M )

MEI Pharma, Inc. Rakipler

ProMIS Neurosciences

NasdaqCM:PMN

US$18.5m

Kairos Pharma

NYSEAM:KAPA

US$21.8m

Enlivex Therapeutics

NasdaqCM:ENLV

US$22.9m

NeuroBo Pharmaceuticals

NasdaqCM:NRBO

US$20.9m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti MEI Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.84
52 Haftanın En Yüksek Seviyesi	US$6.91
52 Haftanın En Düşük Seviyesi	US$2.61
Beta	0.71
11 Aylık Değişim	4.03%
3 Aylık Değişim	-8.68%
1 Yıllık Değişim	-53.75%
33 Yıllık Değişim	-95.79%
5 Yıllık Değişim	-92.72%
Halka arzdan bu yana değişim	-99.97%

Son Haberler & Güncellemeler

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Feb 17

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Dec 30

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Nov 19

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

May 18

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Mar 26

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

Feb 12

MEI Pharma: Another PI3K Delta Progressing To The FDA

Feb 01

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

Dec 02

The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Feb 11

Hissedar Getirileri

	MEIP	US Biotechs	US Pazar
7D	-0.7%	4.0%	2.0%
1Y	-53.7%	18.0%	32.4%

Getiri vs. Endüstri: MEIP geçen yıl % 18 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: MEIP geçen yıl % 32.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is MEIP's price volatile compared to industry and market?
MEIP volatility
MEIP Average Weekly Movement	5.8%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: MEIP son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: MEIP 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	28	Jay File	meipharma.com

Klinik aşamalı bir ilaç şirketi olan MEI Pharma, Inc. kanser tedavisi için çeşitli tedavilerin geliştirilmesine odaklanmaktadır. İnsan epidermal büyüme faktörü reseptörü 2 negatif meme kanseri, kolorektal kanser ve solid tümörleri tedavi etmek için intravenöz küçük moleküllü bir mitokondriyal oksidatif fosforilasyon inhibitörü olan ME-344'ü geliştirmektedir. Şirket daha önce Marshall Edwards, Inc. olarak biliniyordu ve Temmuz 2012'de adını MEI Pharma, Inc. olarak değiştirdi.

MEI Pharma, Inc. Temel Bilgiler Özeti

MEI Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MEIP temel i̇stati̇sti̇kler
Piyasa değeri	US$18.39m
Kazançlar(TTM)	-US$46.60m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.4x

F/K Oranı

MEIP aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MEIP gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$14.38m
Brüt Kâr	-US$14.38m
Diğer Giderler	US$32.23m
Kazançlar	-US$46.60m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-6.99
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

MEIP uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MEIP Stoklara Genel Bakış

Risk Analizi

MEI Pharma, Inc. Rakipler

NasdaqCM:PMN

US$18.5m

NYSEAM:KAPA

US$21.8m

NasdaqCM:ENLV

US$22.9m

NasdaqCM:NRBO

US$20.9m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

MEI Pharma, Inc., Annual General Meeting, Jan 30, 2025

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

Recent updates

MEI Pharma, Inc., Annual General Meeting, Jan 30, 2025

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023

MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Consensus revenue estimates increase by 61%

Price target decreased by 12% to US$2.27

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Price target decreased to US$2.90

MEI Pharma, Inc. Initiates Realignment of Its Clinical Development Efforts

Consensus revenue estimates increase by 26%

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Price target increased to US$5.83

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MEI Pharma, Inc. Announces Not Stand for Re-Election of Directors

MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022

MEI Pharma, Inc. Announces Not Stand for Re-Election of Cheryl L. Cohen as Member of the Board of Directors

Mei Pharma Announces Changes to Board of Directors

MEI Pharma, Inc. Announces Board Changes

Consensus forecasts updated

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MEI Pharma, Inc. to Report Fiscal Year 2022 Results on Sep 08, 2022

Price target decreased to US$4.81

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma, Inc. announced delayed 10-Q filing

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

MEI Pharma Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 11%

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

MEI Pharma, Inc. Announces New Key Executive Appointments

No longer forecast to breakeven

MEI Pharma: Another PI3K Delta Progressing To The FDA

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

Consensus revenue estimates fall to US$38.1m

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma